VAMP Optima closed blood sampling system

K180275 · Edwards Lifesciences, LLC · KRA · Oct 24, 2018 · Cardiovascular

Device Facts

• Record ID: K180275
• Device Name: VAMP Optima closed blood sampling system
• Applicant: Edwards Lifesciences, LLC
• Product Code: KRA · Cardiovascular
• Decision Date: Oct 24, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.1210
• Device Class: Class 2

Intended Use

The blood sampling system is indicated for use on patients requiring periodic withdrawal of blood samples from arterial and central line catheters, including peripherally inserted central catheters and central venous catheters, which are attached to pressure monitoring lines.

Device Story

VAMP Optima is a sterile, single-use, needleless closed blood sampling system; designed to reduce infection, needle sticks, and blood waste. Device connects to pressure monitoring lines, central venous catheters, PICCs, and arterial catheters. Operates by drawing blood from the catheter into a reservoir, allowing undiluted sample collection from an in-line site (Z-site or Luer Access Sample Site); system is then flushed clear. Used in clinical settings by healthcare providers. Output is a blood sample for diagnostic testing. Benefits include safer blood withdrawal and reduced blood loss compared to traditional sampling methods.

Clinical Evidence

Bench testing only. No clinical data. Testing included packaging, shelf life, sterilization, biocompatibility, chemical characterization, human factors, and pre-clinical bench studies performed per ISO 10993-1, ISO 11607-1/-2, ISO 11135, ASTM F2503-13, and FDA guidance for Intravascular Administration Sets.

Technological Characteristics

Sterile, single-use, needleless closed blood sampling system. Components include reservoir, three-way valve, and sampling sites (Z-site or LASS). MR Conditional. Compatible with FloTrac sensors and TruWave disposable pressure transducers. Sterilized per ISO 11135. Materials and processes consistent with predicate device.

Indications for Use

Indicated for patients requiring periodic blood withdrawal from arterial and central line catheters (including PICCs and CVCS) attached to pressure monitoring lines.

Regulatory Classification

Identification

A continuous flush catheter is an attachment to a catheter-transducer system that permits continuous intravascular flushing at a slow infusion rate for the purpose of eliminating clotting, back-leakage, and waveform damping.

Predicate Devices

• VAMP Plus Venous/Arterial Blood Management Protection System (K161962)

Reference Devices

• TruWave disposable pressure transducer (K142749)
• FloTrac sensor (K152980)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" underneath in a smaller font.

October 24, 2018

Edwards Lifesciences LLC Jennifer Wilbur Manager, Regulatory Affairs, Program Management One Edwards Way Irvine, California 92614

Re: K180275

Trade/Device Name: VAMP Optima closed blood sampling system Regulation Number: 21 CFR 870.1210 Regulation Name: Continuous Flush Catheter Regulatory Class: Class II Product Code: KRA Dated: January 30, 2018 Received: January 31, 2018

Dear Jennifer Wilbur:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrl/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

{1}------------------------------------------------

801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

Fernando Aguel Fernando Aguel -S

for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

# Indications for Use

510(k) Number (if known)

### K180275

#### Device Name

VAMP Optima closed blood sampling system

Indications for Use (Describe)

To be used only for blood withdrawal.

The blood sampling system is indicated for use on patients requiring periodic withdrawal of blood samples from arterial and central line catheters, including peripherally inserted central venous catheters, which are attached to pressure monitoring lines.

> Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

## CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# SECTION 5 - 510(k) SUMMARY

| 510(k) Submitter | Edwards Lifesciences, LLC | |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Establishment<br>Registration<br>Number | 2015691 | |
| Address | One Edwards Way<br>Irvine, CA 92614<br>Phone: [phone] | |
| Contact Person | Jennifer Wilbur<br>Manager, Regulatory Affairs Program Management<br>Edwards Lifesciences<br>One Edwards Way<br>Irvine, CA 92614<br>Email: [e-mail]<br>Office: 949-756-4436<br>Fax: [phone] | |
| Date Prepared | January 30, 2018 | |
| Trade Name | VAMP Optima closed blood sampling system | |
| Common Name | Closed Blood Sampling System | |
| Classification Name | Catheter, Continuous Flush (21 CFR 870.1210)<br>Stopcock, I.V. Set and Intravascular administration set (21 CFR 880.5440) | |
| Regulation<br>Class/Product Code | Class II<br>KRA, FMG, FPA | |
| Predicate Device(s) | K161962: VAMP Plus Venous/Arterial Blood Management Protection<br>System | |
| Device Description | The subject Edwards Lifesciences VAMP Optima closed blood sampling<br>system is a sterile, single-use device that provides a safe and<br>convenient method for the withdrawal of blood samples from pressure<br>monitoring lines. The subject device is a needleless, closed blood<br>sampling system designed to reduce infection, needle sticks, and blood<br>waste associated with blood sampling.<br>The VAMP Optima closed blood sampling system is designed for use<br>with disposable pressure transducers and for connection to central line<br>catheters (inclusive of peripherally inserted central catheters and central<br>venous catheters) and arterial catheters where the system can be<br>flushed clear after sampling. The VAMP Optima closed blood sampling<br>system is used for the drawing and retention of heparinized or non-<br>heparinized blood from the catheter or cannula within the line, allowing<br>undiluted blood samples to be drawn from an in-line sampling site. At<br>the completion of sample drawing, the blood or mixed heparin and blood | |
| | To be used only for blood withdrawal. | |
| Indications for<br>Use/Intended Use | The blood sampling system is indicated for use on patients requiring<br>periodic withdrawal of blood samples from arterial and central line<br>catheters, including peripherally inserted central catheters and central<br>venous catheters, which are attached to pressure monitoring lines. | |
| Models | Model<br>Number | VAMP Optima closed blood sampling system models<br>Model Description |
| | VOPTIMA | VAMP Optima with Z-site + COMBICAP caps, 10-pack |
| | VOPTIMAL | VAMP Optima with LASS + COMBICAP caps, 10-pack |
| | MHD8VZ | FloTrac sensor + IV Set + VAMP Optima with Z-site + COMBICAP caps, single pack |
| | MHD8VZ5 | FloTrac sensor + IV Set + VAMP Optima with Z-site + COMBICAP caps, 5-pack |
| | MHD8VRL | FloTrac sensor + IV Set + VAMP Optima with LASS + COMBICAP caps + red striped tubing, single pack |
| | MHD8VRL5 | FloTrac sensor + IV Set + VAMP Optima with LASS + COMBICAP caps + red stopcock inserts + red<br>striped tubing, 5-pack |
| | MHD8VZTW | FloTrac sensor + IV Set + TruWave DPT + VAMP Optima with Z-site, + COMBICAP caps + blue<br>striped tubing, 5-pack |
| | MHD8VLTW | FloTrac sensor + IV Set + TruWave DPT + VAMP Optima with LASS + COMBICAP caps + red striped<br>tubing + blue striped tubing, 5-pack |
| | MHDQ8VZ | FloTrac IQ sensor + IV Set + VAMP Optima with Z-site + COMBICAP caps, single pack |
| | MHDQ8VZ5 | FloTrac IQ sensor + IV Set + VAMP Optima with Z-site + COMBICAP caps, 5-pack |
| | MHDQ8VRL | FloTrac IQ sensor + IV Set + VAMP Optima with LASS + COMBICAP caps + red striped tubing,<br>single pack |
| | MHDQ8VRL5 | FloTrac IQ sensor + IV Set + VAMP Optima with LASS + COMBICAP caps + red striped tubing, 5-<br>pack |
| MHDQ8VZTW | FloTrac IQ sensor + IV Set + TruWave DPT + VAMP Optima with Z-site + COMBICAP caps +<br>blue striped tubing, 5-pack | |
| MHDQ8VLTW | FloTrac IQ sensor + IV Set + TruWave DPT + VAMP Optima with LASS + COMBICAP caps + red<br>striped tubing + blue striped tubing, 5-pack | |

{4}------------------------------------------------

{5}------------------------------------------------

| Comparative<br>Analysis | The modified VAMP Optima closed blood sampling system has the<br>following similarities to the predicate VAMP Plus device:<br>has the same indications for use, intended use and<br>contraindications, uses the same operating principle, has similar technological characteristics, built from the same type of components, incorporates the same basic reservoir design, utilizes many of the same materials, includes the option for a Z-site sample site, is MR Conditional, contains an IV set, compatible with a TruWave disposable pressure transducer<br>(K142749), is packaged and sterilized using the same materials and<br>processes The following proposed changes from the VAMP Plus to the VAMP<br>Optima closed blood sampling system are the subject of this 510(k)<br>submission. These differences are not a fundamental change in<br>scientific technology and have no impact to the intended use or<br>indications for use. Expansion of sampling site offerings beyond the current Z-site to<br>include a needleless Luer Access Sample Site (LASS), Modification to subassembly components: Modification from a two position one-way valve to a four<br>position three-way valve Modification to the reservoir from a one port to a two port<br>syringe body in order to align with the three-way valve<br>design Dimensional and cosmetic modifications to the reservoir<br>and reservoir bracket Pressure tubing, IV Set and adhesive material changes, Male luer lock connector change, Designed to be compatible with a FloTrac sensor (K152980) |
|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Functional/ Safety<br>Testing | The VAMP Optima closed blood sampling system has successfully<br>passed functional and performance testing, including packaging, shelf<br>life, sterilization, biocompatibility, chemical characterization, human<br>factors, pre-clinical testing and bench studies. Testing was performed in<br>accordance with the following standards: ISO 10993-1, ISO 11607-1/-2,<br>ISO 11135, ASTM F2503-13 and FDA's 2008 device-specific guidance<br>"Intravascular Administration Sets Premarket Notification Submissions<br>[510(k)]." |
| Conclusion | The Edwards Lifesciences VAMP Optima closed blood sampling system<br>has been demonstrated to be substantially equivalent to the predicate<br>VAMP Plus Venous/Arterial Blood Management Protection System<br>(K161962). |